Titre :

Relationships between Circulating Sclerostin, Bone Marrow Adiposity, Other Adipose Deposits and Lean Mass in Post-Menopausal Women.

Auteur(s) :

Courtalin, Marion [Auteur]
Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490 [MABLab]
Bertheaume, Nicolas [Auteur]
Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490 [MABLab]
Badr, S. [Auteur]
During, Alexandrine [Auteur]
Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490 [MABLab]
Lombardo, D. [Auteur]
Deken, Valerie [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Cortet, Bernard [Auteur]
Marrow Adiposity & Bone Lab [MABLab] - ULR 4490
Marrow Adiposity & Bone Lab (MABLab) - ULR 4490
Clabaut, Aline [Auteur]
Marrow Adiposity & Bone Lab (MABLab) - ULR 4490
Marrow Adiposity & Bone Lab [MABLab] - ULR 4490
Paccou, Julien [Auteur]
Marrow Adiposity & Bone Lab [MABLab] - ULR 4490
Marrow Adiposity & Bone Lab (MABLab) - ULR 4490

Titre de la revue :

Int J Mol Sci

Nom court de la revue :

Int J Mol Sci

Numéro :

24

Pagination :

5922

Date de publication :

2023-03-21

ISSN :

1422-0067

Mot(s)-clé(s) en anglais :

bone marrow adiposity
sclerostin
Dixon method
MRI
post-menopausal women
osteoporosis
lean mass
adipose deposit

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Sclerostin is a Wnt signaling pathway inhibitor that negatively regulates bone formation. Bone-marrow-derived stromal cell (BMSC) differentiation is influenced by the Wnt pathway, leading to the hypothesis that higher ...
Lire la suite >Sclerostin is a Wnt signaling pathway inhibitor that negatively regulates bone formation. Bone-marrow-derived stromal cell (BMSC) differentiation is influenced by the Wnt pathway, leading to the hypothesis that higher levels of sclerostin might be associated with an increase in bone marrow adiposity (BMA). The main purpose of this study was to determine whether a relationship exists between circulating sclerostin and BMA in post-menopausal women with and without fragility fractures. The relationships between circulating sclerostin and body composition parameters were then examined. The outcomes measures included vertebral and hip proton density fat fraction (PDFF) using the water fat imaging (WFI) MRI method; DXA scans; and laboratory measurements, including serum sclerostin. In 199 participants, no significant correlations were found between serum sclerostin and PDFF. In both groups, serum sclerostin was correlated positively with bone mineral density (R = 0.27 to 0.56) and negatively with renal function (R = −0.22 to −0.29). Serum sclerostin correlated negatively with visceral adiposity in both groups (R = −0.24 to −0.32). Serum sclerostin correlated negatively with total body fat (R = −0.47) and appendicular lean mass (R = −0.26) in the fracture group, but not in the controls. No evidence of a relationship between serum sclerostin and BMA was found. However, serum sclerostin was negatively correlated with body composition components, such as visceral adiposity, total body fat and appendicular lean mass.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2023-11-15T02:16:55Z
2024-01-11T10:51:31Z